Rxwire
In the news · 48h FDA 37 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AstraZeneca 3 Novo Nordisk 3 AbbVie 2
Trials & R&D · first seen 8h ago, updated 8h ago

MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests

1 outlet Merck & Co. (MSD)

While MSD has proven remigromig non-inferior to Lucentis in terms of efficacy in DME, questions around its tolerability remain. The post MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests appeared first on Clinical Tr…

Summary from Clinical Trials Arena.

Coverage 1 article · 1 outlet

  1. Clinical Trials Arena
    MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests